Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma

Part of paid clinical trials in Sarasota, Florida.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT07218315
Status
Recruiting
Apply to this trial

Conditions

  • Thyroid Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • CellFX nsPFA Percutaneous Electrode System — DEVICE
    Patients will undergo thyroid ablation with the CellFX nsPFA system, an outpatient procedure under local anesthesia, or intravenous sedation.

Study Details

This study is to evaluate the effectiveness of nsPFA in treating papillary thyroid microcarcinoma. T

Key Dates

Start date
Feb 11, 2026
Status verified
May 2026
Primary completion
Jan 31, 2029
Completion
Jan 31, 2031

Study Design

Enrollment
15 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment with nsPFA
    Participants will undergo thyroid ablation with the CellFX nsPFA system, an outpatient procedure under local anesthesia, or intravenous sedation.

Primary Outcome Measure

Safety and Adverse Events (AEs) [ Time Frame: Through study completion; an average of 1 year ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Sarasota Memorial HospitalSarasotaFlorida34239
Ralph Tufano, MD
[email protected]
713-563-7600
Ralph Tufano, MD (PRINCIPAL_INVESTIGATOR)
The University of Texas M. D. Anderson Cancer CenterHoustonTexas77030
Victoria E Banuchi, MPH
[email protected]
713-563-5459
Victoria E Banuchi, MPH (PRINCIPAL_INVESTIGATOR)

Find similar trials in Sarasota, FL

By research site
Sarasota Memorial Hospital· Sarasota, FLThe University of Texas M. D. Anderson Cancer Center· Houston, TX

Related Studies